Safety and Tolerability of Recombinant Bet v 1 (rBet v 1) Tablets in Sublingual Immunotherapy (SLIT)

Safety and Tolerability of Recombinant Bet v 1 (rBet v 1) Tablets in Sublingual Immunotherapy (SLIT)

Two randomised, double-blind, placebo-controlled studies were performed in order to investigate the safety and tolerability of SLIT tablets with rBet v 1 (given as single rising doses and in multi-dose regimens) in birch-pollen-allergic patients.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of allergy and clinical immunology 2009-02, Vol.123 (2), p.S215-S215
Hauptverfasser: Winther, L, Poulsen, L.K, Robin, B, Mélac, M, Malling, H
Format: Artikel
Sprache:eng
Schlagworte:
Allergy and Immunology
Medical research
Medical treatment
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Two randomised, double-blind, placebo-controlled studies were performed in order to investigate the safety and tolerability of SLIT tablets with rBet v 1 (given as single rising doses and in multi-dose regimens) in birch-pollen-allergic patients.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2008.12.822